Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.
about
Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's diseaseEvolving concepts: how diet and the intestinal microbiome act as modulators of breast malignancySystematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoeaDeveloping a metagenomic view of xenobiotic metabolismMultiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signalingIn vivo imaging of systemic transport and elimination of xenobiotics and endogenous molecules in mice.Organ data from the developing Göttingen minipig: first steps towards a juvenile PBPK model.High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites.Three measurable and modifiable enteric microbial biotransformations relevant to cancer prevention and treatment.Enterohepatic recirculation of bioactive ginger phytochemicals is associated with enhanced tumor growth-inhibitory activity of ginger extract.Liver zonation: Novel aspects of its regulation and its impact on homeostasis.Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.Systematic review: the management of chronic diarrhoea due to bile acid malabsorption.Drug structure-transport relationshipsThe fate of microcystins in the environment and challenges for monitoring.A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma.Single and multiple dose pharmacokinetics and tolerability of HX-1171, a novel antioxidant, in healthy volunteersEffect of dose escalation on the in vivo oral absorption and disposition of glycylsarcosine in wild-type and Pept1 knockout mice.Gut bacteria require neutrophils to promote mammary tumorigenesis.Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients.Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage.Antibiotic Exposure and Juvenile Idiopathic Arthritis: A Case-Control StudyCompartmental pharmacokinetic analysis of oral amprenavir with secondary peaksHepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.IMMUNOLOGY. Breaching the gut-vascular barrier.Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.Gastrointestinal microbiome and breast cancer: correlations, mechanisms and potential clinical implications.Effect of dietary probiotic supplementation on intestinal microbiota and physiological conditions of Nile tilapia (Oreochromis niloticus) under waterborne cadmium exposure.Glucuronides in the gut: Sugar-driven symbioses between microbe and host.Acetaminophen overdose associated with double serum concentration peaks.Association of markers of chronic viral hepatitis and blood mercury levels in US reproductive-age women from NHANES 2001-2008: a cross-sectional study.Serum protein adsorption and excretion pathways of metal nanoparticles.Methods to evaluate biliary excretion of drugs in humans: an updated review.Use of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates.The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling.Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.
P2860
Q24564761-13ACC523-73A4-4CDA-ABB1-FEFC6A13DEDFQ27007784-91D5E054-FBAD-457F-B8B5-8EFB1729C30DQ28081213-D72CC238-EEC6-4313-80E4-CD85C97C653BQ28273307-A7FC09D2-7466-40E1-8F83-635BCF9E8CF5Q28568378-90901DE6-A868-4EF6-98AB-A2500E4ED3D0Q30839160-90132863-49D8-44DD-8079-1D7AD181E770Q31033069-B64B6EEB-34B8-486C-A60C-94A60163E73CQ33439410-64A63D14-653B-428F-B217-544D7C1B7FDEQ33648565-0C800A2E-C953-4CAC-8A41-31ED5F9AA6C9Q33705263-6E57F034-9472-4660-8CB5-CE93563DB3F6Q33886995-AAE81AB9-ECC5-44C6-B731-EC162328B4EDQ34045240-5E03C476-7699-4A60-B76C-780F18A5A0B0Q34408666-5024C540-B16A-42AB-A653-14C549F10BD4Q34420259-D27B8539-A18E-4D3A-8E2B-F19C916C6BFFQ34792606-825C9D49-8408-477D-8750-26DAFC6DAEA2Q35073752-3684E66B-F23D-41E7-A0EA-308448C08039Q35223225-2E138661-DA04-4EEB-8B8E-FE537E686790Q35579541-A03EC848-E320-493F-85A5-C53071F0CBE9Q35592111-DCE5FFD7-E494-47E4-9C84-DFB80C1879E2Q35598398-C2714434-7B9A-4EAD-9C65-1C943100DB01Q35619332-51E8FC9E-609F-47A7-AEE0-D1F62A31113BQ35660108-269694C3-F0CE-4CFA-BB1E-87EC73C77839Q35701575-DA881691-7139-462A-BED1-AB10739E91DEQ35759067-5D00A7BA-B183-4AE4-9D40-9DB546D55215Q35812091-E1F5AA72-81F1-4E3F-9C78-45A31827C3FBQ35826366-52ECB62E-2E1C-48A7-88F6-48F0D79745FEQ35840447-F6713803-645B-4861-B53C-0156BBA93A5BQ35967888-A248C7C6-DD05-4F65-AEDC-FA6324EE8E87Q36111207-7F70DA49-294A-428E-A950-08DBCB51DF45Q36154657-2201FD6A-E1F5-4C85-8A06-9F86E7D38845Q36234256-84A7C069-DEBE-417E-9BB0-6180FEDD0136Q36340552-017301DA-BF31-4E11-90DA-FD678E1D5BCAQ36367854-7E996C4B-8E87-404F-AFD6-4DCBA77E40A5Q36439086-6F068CBA-0E55-473C-892F-997D2CB09A69Q36468223-E6B6C07C-9A6F-4577-B359-A94D726221B6Q36495774-25B3E989-A0B9-4F07-A823-4A155A273892Q36544962-ED8F1BE3-AD69-4831-B986-F65C0EFBE217Q36599937-C1A6FEC1-7F21-4691-A8B6-CA2E502B7C86Q36629237-48805F58-BBE0-49B5-9810-184DD92ADE52Q36792638-7C61C962-5E98-40D7-A0F7-2869CD1702A5
P2860
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.
@ast
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.
@en
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.
@nl
type
label
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.
@ast
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.
@en
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.
@nl
prefLabel
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.
@ast
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.
@en
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.
@nl
P2093
P1476
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.
@en
P2093
Beatrice M Magnusson
Frank J Burczynski
Michael S Roberts
Michael Weiss
P304
P356
10.2165/00003088-200241100-00005
P577
2002-01-01T00:00:00Z
P6179
1030243610